scholarly journals Antimicrobial resistance in clinical isolates of Ureaplasma spp. from samples in Germany

2021 ◽  
Author(s):  
Roger Dumke
Keyword(s):  
Antimicrobial Resistance ◽  
Ureaplasma Urealyticum ◽  
Urogenital Tract ◽  
Molecular Methods ◽  
Clinical Isolates ◽  
University Hospital ◽  
Minimal Inhibitory Concentrations ◽  
Ureaplasma Spp

Ureaplasma urealyticum and U. parvum are mollicutes species that colonize the urogenital tract of many asymptomatic persons but are also thought to be associated with symptomatic infections. Using 170 strains isolated between 2016 and 2019 in a German university hospital, resistance was tested by a combination of commercial tests, molecular methods and determination of minimal inhibitory concentrations. Rates of resistance to macrolides, tetracyclines and fluoroquinolones were 0%, 4.1% and 7.1%, respectively.

scholarly journals In-vitro activity of lipoic acid against Ureaplasma urealyticum and Ureaplasma parvum isolated from women with infections of the urogenital tract. A pilot study

2020 ◽  
Author(s):  
Małgorzata Biernat-Sudolska ◽  
Danuta Rojek-Zakrzewska ◽  
Anna Bilska-Wilkosz
Keyword(s):  
Lipoic Acid ◽  
Color Change ◽  
Ureaplasma Urealyticum ◽  
Current Data ◽  
Urogenital Tract ◽  
Reduced Form ◽  
Ureaplasma Parvum ◽  
Tract Infections ◽  
Ureaplasma Spp

Several species of Ureaplasma bacteria are known to be present in the urogenital tract of humans, in both healthy individuals and symptomatic patients. These pathogens are associated with urogenital tract infections, infertility problems and spontaneous abortion in humans. The present study involved 77 strains of Ureaplasma species (Ureaplasma spp.), including 21 Ureaplasma urealyticum (U. urealyticum) strains and 56 Ureaplasma parvum (U. parvum) strains. Lipoic acid (LA) and its reduced form dihydrolipoic acid (DHLA) are synthesized in all prokaryotic and eukaryotic cells. Research of recent years increasingly points to therapeutic properties of exogenously supplemented LA. In our study, we examined for the first time the effect of LA on the bacteria multiplication and its bactericidal activity against U. urealyticum and U. parvum. The LA concentrations used were: 1200 µg/ml, 120 µg/ml, and 12 µg/ml. The titer for each strain of Ureaplasma spp. was estimated using the color changing units (CCU) assay. For CCU measurements, a series of 10-fold dilutions of each cell culture in 0.9% NaCl (titration) was prepared and 1 CCU/ml was defined as the highest dilution of cells at which color change was detected. The strongest bacteriostatic and bactericidal effect of LA was observed at a concentration of 1200 µg/ml. In contrast, at lower LA concentrations, stimulation of the bacteria multiplication was noted for 14% of the total number of strains tested. Taken together, the current data provide novel findings about potential beneficial antimicrobial effects of LA.

scholarly journals Five-year Pan-European, longitudinal surveillance of Clostridium difficile ribotype prevalence and antimicrobial resistance: the extended ClosER study

2019 ◽  
Vol 39 (1) ◽  
pp. 169-177 ◽  
Author(s):  
Jane Freeman ◽  
◽  
Jonathan Vernon ◽  
Sally Pilling ◽  
Kirsti Morris ◽  
...  
Keyword(s):  
Clostridium Difficile ◽  
Antimicrobial Resistance ◽  
Antimicrobial Susceptibility ◽  
Geometric Mean ◽  
Resistant Isolate ◽  
Recurrence Rates ◽  
Minimal Inhibitory Concentrations ◽  
Pearson Coefficient ◽  
Faecal Samples

AbstractClostridium difficile infection (CDI) has been primarily treated with metronidazole or vancomycin. High recurrence rates, the emergence of epidemic PCR ribotypes (RTs) and the introduction of fidaxomicin in Europe in 2011 necessitate surveillance of antimicrobial resistance and CDI epidemiology. The ClosER study monitored antimicrobial susceptibility and geographical distribution of C. difficile RTs pre- and post-fidaxomicin introduction. From 2011 to 2016, 28 European countries submitted isolates or faecal samples for determination of PCR ribotype, toxin status and minimal inhibitory concentrations (MICs) of metronidazole, vancomycin, rifampicin, fidaxomicin, moxifloxacin, clindamycin, imipenem, chloramphenicol and tigecycline. RT diversity scores for each country were calculated and mean MIC results used to generate cumulative resistant scores (CRSs) for each isolate and country. From 40 sites, 3499 isolates were analysed, of which 95% (3338/3499) were toxin positive. The most common of the 264 RTs isolated was RT027 (mean prevalence 11.4%); however, RT prevalence varied greatly between countries and between years. The fidaxomicin geometric mean MIC for years 1–5 was 0.04 mg/L; only one fidaxomicin-resistant isolate (RT344) was submitted (MIC ≥ 4 mg/L). Metronidazole and vancomycin geometric mean MICs were 0.46 mg/L and 0.70 mg/L, respectively. Of prevalent RTs, RT027, RT017 and RT012 demonstrated resistance or reduced susceptibility to multiple antimicrobials. RT diversity was inversely correlated with mean CRS for individual countries (Pearson coefficient r = − 0.57). Overall, C. difficile RT prevalence remained stable in 2011–2016. Fidaxomicin susceptibility, including in RT027, was maintained post-introduction. Reduced ribotype diversity in individual countries was associated with increased antimicrobial resistance.

scholarly journals Determination of In Vitro Antimicrobial Susceptibility for Lefamulin (Pleuromutilin) for Ureaplasma Spp. and Mycoplasma hominis

Antibiotics ◽  
2021 ◽  
Vol 10 (11) ◽  
pp. 1370
Author(s):  
Oliver Spiller-Boulter ◽  
Susanne Paukner ◽  
Ian Boostrom ◽  
Kirsty Sands ◽  
Edward A. R. Portal ◽  
...  
Keyword(s):  
Ureaplasma Urealyticum ◽  
Acquired Resistance ◽  
Mycoplasma Hominis ◽  
Fold Increase ◽  
23S Rrna ◽  
Ureaplasma Parvum ◽  
Urogenital Infections ◽  
Ureaplasma Spp

Lefamulin is the first of the pleuromutilin class of antimicrobials to be available for therapeutic use in humans. Minimum inhibitory concentrations of lefamulin were determined by microbroth dilution for 90 characterised clinical isolates (25 Ureaplasma parvum, 25 Ureaplasma urealyticum, and 40 Mycoplasma hominis). All Mycoplasma hominis isolates possessed lefamulin MICs of ≤0.25 mg/L after 48 h (MIC50/90 of 0.06/0.12 mg/L), despite an inherent resistance to macrolides; while Ureaplasma isolates had MICs of ≤2 mg/L after 24 h (MIC50/90 of 0.25/1 mg/L), despite inherent resistance to clindamycin. Two U. urealyticum isolates with additional A2058G mutations of 23S rRNA, and one U. parvum isolate with a R66Q67 deletion (all of which had a combined resistance to macrolides and clindamycin) only showed a 2-fold increase in lefamulin MIC (1–2 mg/L) relative to macrolide-susceptible strains. Lefamulin could be an effective alternative antimicrobial for treating Ureaplasma spp. and Mycoplasma hominis infections irrespective of intrinsic or acquired resistance to macrolides, lincosamides, and ketolides. Based on this potent in vitro activity and the known good, rapid, and homogenous tissue penetration of female and male urogenital tissues and glands, further exploration of clinical efficacy of lefamulin for the treatment of Mycoplasma and Ureaplasma urogenital infections is warranted.

scholarly journals A Cross-Canada Surveillance of Antimicrobial Resistance in Respiratory Tract Pathogens

1999 ◽  
Vol 10 (2) ◽  
pp. 128-133 ◽  
Author(s):  
Ross J Davidson ◽  
Canadian Bacterial Surveillance Network ◽  
Donald E Low
Keyword(s):  
Antimicrobial Resistance ◽  
Clinical Laboratory ◽  
Clinical Isolates ◽  
National Committee ◽  
Beta Lactamase ◽  
Beta Lactam ◽  
Minimal Inhibitory Concentrations ◽  
Beta Lactam Antibiotics ◽  
Significant Difference ◽  
High Level

OBJECTIVE: To determine the prevalence of antimicrobial resistance in clinical isolates ofStreptococcus pneumoniae, Haemophilus influenzaeandMoraxella catarrhalisfrom medical centres across Canada.METHODS: Fifty laboratories from across Canada were asked to collect up to 25 consecutive clinical isolates ofS pneumoniae,H influenzaeandM catarrhalisat some time between September 1994 and May 1995, and then again between September and December of 1996. A total of 2364S pneumoniae, 575H influenzaeand 200M catarrhalissamples were collected.H influenzaeandM catarrhalisisolates were tested for the production of beta-lactamase.S pneumoniaeisolates were characterized as penicillin susceptible, intermediately resistant or high level penicillin-resistant. Minimal inhibitory concentrations (MICs) were determined using a microbroth dilution technique described by the National Committee of Clinical Laboratory Standards.RESULTS: Between the two collection periods, there was a significant increase in highly penicillin-resistantS pneumoniaefrom 2.1% to 4.4% (P<0.05) and an increase in intermediately penicillin-resistant strains from 6.4% to 8.9% (P<0.05). A significant increase in high level penicillin-resistantS pneumoniaewas noted among paediatric isolates. No significant difference in the susceptibilities of comparator agents was detected. A significant increase in the number of beta-lactamase producingH influenzae, 34% to 43% (P<0.05) was observed. Ninety-five per cent ofM catarrhalisisolates were beta-lactamase producers in both time periods.CONCLUSIONS: During the course of this study, the incidence of penicillin resistance inS pneumoniaedoubled. As a result of this increase, infections due to this organism in sites where poor penetration of beta-lactam antibiotics occur may become increasingly difficult to manage.

scholarly journals Secular trends in incidence and antimicrobial resistance among clinical isolates of salmonella at a university hospital in Taiwan, 1983–1999

2001 ◽  
Vol 127 (2) ◽  
pp. 207-213 ◽  
Author(s):  
L. H. SU ◽  
C. H. CHIU ◽  
A. J. KUO ◽  
J. H. CHIA ◽  
C. F. SUN ◽  
...  
Keyword(s):  
Antimicrobial Resistance ◽  
Antimicrobial Agents ◽  
Secular Trends ◽  
Clinical Isolates ◽  
University Hospital ◽  
The Future

The incidence and antimicrobial resistance among clinical isolates of salmonella at a university hospital in Taiwan between 1983 and 1999 are summarized in this report. A total of 7986 isolates were analysed. Serogroup B has been the most prevalent over the years, with an apparently continuous decline after 1995. Concordant decrease was also found among S. choleraesuis and S. typhi isolates in recent years. In contrast, the proportion of serogroup D strains increased significantly after 1996. S. typhi remained relatively susceptible to most of the antimicrobial agents examined. For non-typhoidal isolates, antimicrobial resistance to ampicillin (62%), chloramphenicol (67%), and sulfamethoxazole-trimethoprim (37%) was relatively higher than that reported elsewhere. Newer generation cephalosporins and fluoroquinolones remained effective over the years, although emerging resistance to these drugs has been noticed since 1992. A more prudent selection and use of antimicrobial agents, in both humans and animals, and a continuous surveillance of resistance are essential in the future.

Sign in / Sign up

Export Citation Format

Share Document